EXAGEN (XGN) Director Kim Paul Receives 37,500-Share Option Award

What Happened Kim Paul, a director of EXAGEN Inc. (XGN), received a derivative award on June 9, 2026 covering 37,500 shares. The grant is reported as an award/acquisition (code A) with $0.00 listed as the acquisition price, indicating an option/award rather than an open-market purchase of shares.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-08-19 (filing appears late relative to the transaction date).
• Security: derivative/option covering 37,500 shares; reported acquisition price: $0.00.
• Vesting: The entire option becomes fully vested and exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of stockholders, subject to continued service on the board (per footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: This Form 4 was submitted more than two months after the grant date; late filings can limit the timeliness of market insight.

Context This was an equity compensation award (option/derivative), not an open-market buy or sale. Such grants are commonly used for director compensation and do not by themselves indicate immediate buying or selling of shares. The award vests on a future date and would convert to exercisable options/shares only if vesting conditions are met.